Oxford BioDynamics PLC OBD signs fifth collaboration agreement

TIDMOBD

Oxford BioDynamics PLC

08 November 2018

08 November 2018

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Oxford BioDynamics signs fifth collaboration agreement in immuno-oncology space

-- Agreement with major US biopharmaceutical company demonstrates value of the wide range of immuno-oncology biomarker applications recently developed using EpiSwitch(TM)

-- High resolution mapping with the EpiSwitch(TM) technology will be used to evaluate risks, linked to the clinical benefit of treatment

Oxford BioDynamics Plc is pleased to announce that it has entered into its fifth collaboration agreement for the development of predictive biomarkers for immuno-oncology (IO) therapeutics.

IO is a fast-growing field, with a number of therapies for the treatment of cancers, in particular immune checkpoint inhibitors, demonstrating a highly efficacious response in certain patients. However, many current IO treatments remain limited in their utility due to a low response rate, and significant subsets of patients not benefiting from a clinically meaningful response to treatment.

There is a need for robust stratification of patients in order to accurately exclude those that will not respond to these IO therapeutics, as well as for strong differentiation of individual IO treatments from alternative therapeutic options. OBD has already established its position in this field with a number of robust biomarker-based predictive patient stratifications for several IO assets, including both PD-1 and PD-L1 inhibitors.

In this further expansion of its technology application, Oxford BioDynamics will use its EpiSwitch(TM) platform to offer high resolution mapping of epigenetic profiles in patients, so that epigenetic risks, in the context of information from other regulatory modalities, could be linked to the clinical benefit of treatment.

This represents the fifth collaboration agreement that Oxford BioDynamics has entered into in the IO field. Financial terms of the agreement are not disclosed.

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

"We are pleased to have entered into this new agreement with a major US biopharmaceutical company in the dynamic field of immuno-oncology, as there is a high need for the identification of epigenetic biomarkers to evaluate drug performance in therapeutic development programmes. This agreement represents the fifth contract we have signed in IO, continuing to validate the potential of our EpiSwitch(TM) technology in this space."

-ENDS-

For further details please contact:

 
 Oxford BioDynamics Plc 
  Christian Hoyer Millar, 
  CEO 
  Paul Stockdale, CFO            [phone] 
 FTI Consulting 
  Financial Public Relations 
  Adviser 
  Brett Pollard 
  Natalie Garland-Collins       [phone] 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRADMMGMZNVGRZZ

(END) Dow Jones Newswires

November 08, 2018 02:01 ET (07:01 GMT)